Home

Hal Barron

CIK 1418677 · SVP - DEVELOPMENT & CMO · last filed 2026-06-08

Hal Barron is a SVP - DEVELOPMENT & CMO who has filed 22 SEC Form 4 insider transactions across 3 companies since 2009. The most recent filing, for QNT, was dated Jun 8, 2026. Across all open-market trades the lifetime net is +$17.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $12.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$12.70M

Companies

3

Total Filings

22

Lifetime Open-Market Net

$17.40M

Filer Profile

Reported Address
C/O GSK PLC
79 NEW OXFORD STREET
LONDON WC1A 1DG
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
QNT Director 255,833 $49.65 $12.70M $15.00M 1 2026-06-08
Juno Therapeutics, Inc. (JUNO) Delisted Director 0 — — $2.40M 13 2018-03-07
Alexza Pharmaceuticals Inc. (ALXA) Delisted Director 3,492 — — $0 7 2013-08-19

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-08 QNT Mixed +255,833 $15.00M EDGAR
2018-03-07 Juno Therapeutics, Inc. (JUNO) Delisted Mixed −103,780 -$9.03M EDGAR
2018-01-09 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) +336 $0 EDGAR
2017-10-06 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) +361 $0 EDGAR
2017-07-07 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) +516 $0 EDGAR
2017-06-19 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) — $0 EDGAR
2017-04-06 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) +698 $0 EDGAR
2017-01-09 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) +768 $0 EDGAR
2016-10-17 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) +438 $0 EDGAR
2016-07-05 Juno Therapeutics, Inc. (JUNO) Delisted Grant (A) +328 $0 EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.